Solving QC Bottlenecks and Enabling Scalable, Fully Automated QC

As cell-therapy manufacturing scales, one challenge keeps emerging in conversations with manufacturers and quality control (QC) leaders: production is scaling, but QC operations are still stuck in the artisanal era. This article represents the beginning of a journey: one that started with recognizing a fundamental truth about cell therapy QC bottlenecks and has evolved into a broader exploration of what it takes to build automation-ready QC testing ecosystems.

The bottleneck isn't where most people think it is. It's not individual assays running too slowly or instruments lacking throughput. The real constraint is architectural; the industry is operating in fragmented environments in which manual workflows, siloed data systems, and rigid operational practices create compounding inefficiencies. QC teams are brilliant at executing tests, but they're drowning in coordination overhead: scheduling conflicts, manual handoffs, disconnected data streams, lack of digitalization, and resource allocation puzzles that consume more time than the science itself.

I've spent considerable time studying how other industries solved similar challenges, with high-throughput diagnostics and drug discovery being the most instructive. These fields already mastered precision, accuracy, and volume using the same analytical instrumentation we're working with today. The difference? They made a fundamental shift in mindset before they made investments in automation. They stopped asking "how do we automate this task?" and started asking "how do we design an ecosystem where automation becomes inevitable?"

That's the fundamental shift required for scalable QC operations, and it's the shift this article explores. Rather than building another standalone assay platform, we asked how to create infrastructure where reagent management, instrument orchestration, and sample tracking function as integrated workflows. We need to stop treating regulatory constraints as limitations and start viewing them as design principles for resilient, scalable systems. We need to borrow lessons from industries that have already navigated this transformation. And most critically, we need to acknowledge that solving QC bottlenecks requires more than new equipment; it requires reimagining the entire operational architecture.

This article outlines the critical thinking, system design principles, and cross-functional changes needed to build fully automated, data-driven QC operations. It explores ecosystem-level considerations, lessons learned from adjacent industries, and the cultural transformation required when you move from "we run tests" to "we operate an integrated platform." Because the future of cell therapy QC isn't about running assays faster, it's about building connected lab environments where speed, consistency, and scalability emerge naturally from the design itself.

Lessons from fully automated industrial-scale screening

My perspective on QC automation is heavily shaped by time spent designing, developing, and optimizing fully automated, industrial-scale drug discovery screening operations. While cell-therapy QC and drug discovery serve very different purposes, the underlying operational challenges and the consequences of getting them wrong are remarkably similar.

In high-throughput screening, failure is not an option. Months and, in some cases, years of upstream research can hinge on a single screening campaign. A single execution failure can invalidate an entire dataset, erode confidence in the results, and force teams to repeat work at enormous cost in time, resources, and momentum. That reality drives a fundamentally different approach to system design: resilience, recoverability, and predictability are treated as nonnegotiable requirements, not aspirational goals.

Data quality is equally unforgiving. Precision and accuracy in liquid handling across samples, reagents, and controls are critical when operating at scale. In a high-throughput environment, even small performance drifts or process variability can cascade into false positives, false negatives, or systematic bias. When the goal is to identify a true signal hidden among tens of thousands of data points, these errors don’t just degrade efficiency; they can fundamentally misdirect scientific decision-making and stall discovery altogether.

Scale further amplifies the need for digital rigor. High-throughput drug screening routinely involves tracking tens of thousands of samples simultaneously, each with distinct states, identities, and processing histories. This is only possible through deeply integrated digital infrastructure: automated inventory management, robust barcoding and scanning, real-time sample state tracking, and tight coupling between physical workflows and data systems. Manual tracking simply does not survive at this scale.

Finally, mature screening environments are designed explicitly to eliminate entire classes of process failures. Cross-contamination, sample transfer errors, mislabeling, and ambiguous sample states are engineered out through standardized hardware, validated workflows, closed-loop verification, and continuous monitoring. These systems assume that humans will make mistakes, and they are built to prevent those mistakes from propagating into data loss or operational failure.

These lessons translate directly to cell-therapy QC. As QC operations scale toward commercial throughput, the question is no longer whether automation is necessary, but whether the surrounding ecosystem is designed to support it. The same principles that enabled reliable, high-throughput drug discovery, system-level thinking, digital traceability, failure-resistant workflows, and design-for-scale rigor are now essential for building the next generation of automated, compliant QC operations.

Using systems-thinking approaches to bring automated workflows together at scale

Traditional QC testing workflows, and the laboratory spaces and infrastructure that support them, were not designed to operate as scalable, high-throughput, fully automated systems. While individual assays and instruments may perform well in isolation, the surrounding ecosystem often relies on manual coordination, fragmented data flows, and localized decision-making. These limitations become increasingly visible as volume increases, turning what once felt manageable into systemic bottlenecks.

Addressing these challenges requires moving beyond point solutions and applying systems-thinking principles to the entire end-to-end QC workflow. Rather than optimizing individual steps in isolation, this approach starts by breaking down all workflow touchpoints, from sample receipt to result reporting, to map process inefficiencies and identify constraints that only emerge at scale. This means explicitly mapping the full process, identifying interconnected elements (people, technologies, data, and physical space), visualizing feedback loops, and analyzing flow to uncover where work accumulates, stalls, or becomes error-prone. Importantly, systems thinking forces consideration of external factors such as regulatory requirements, staffing models, supplier variability, and site-to-site differences, allowing teams to address root causes rather than repeatedly treating symptoms.

Within this framework, reagent, instrument, and sample management are treated as tightly coupled subsystems rather than independent operational domains. Each requires deliberate design to transition from manual, experience-driven execution to automated, predictable, and data-driven workflows. Reagent management must evolve from ad hoc inventory tracking to automated forecasting, kitting, and lot traceability aligned with assay demand. Instrument management must shift from static scheduling and human oversight to dynamic orchestration informed by availability, performance, and maintenance state. Sample management must move away from manual handoffs and spreadsheet tracking toward digitally traceable workflows that preserve the chain of custody while enabling parallelization and batching at scale.

The common thread across these domains is a focus on systematically reducing manual touchpoints while increasing visibility, coordination, and feedback across the system. By designing workflows as integrated components of a single operational ecosystem, rather than as loosely connected steps, QC organizations can build resilience, absorb variability, and scale throughput without linear increases in complexity or headcount. This systems-level perspective is foundational to enabling automated QC operations that are not only faster but also more robust, repeatable, and ready for commercial-scale QC testing.

End-to-end workflow optimization for high-throughput automated QC testing

Once the solutions for high-throughput automated QC testing are mapped, true scalability depends on how rigorously each process step and the supporting infrastructure are optimized as part of an integrated system. Optimization at this stage is not about making individual steps faster in isolation, but about designing workflows that perform predictably, repeatably, and efficiently under sustained commercial-scale demand. Achieving this requires a structured framework of tools, metrics, and experimental approaches that translate system-level intent into operational reality.

At the core of this framework are design of experiments, capacity modeling, and data-driven performance analysis to understand how variability propagates through the workflow. Assay steps, instrument utilization, reagent preparation, sample batching, and data review are evaluated not only for average performance, but for sensitivity to volume, timing, and failure modes. By systematically stress-testing workflows, both digitally and operationally, teams can identify nonobvious constraints such as resource contention, queue buildup, or downstream review delays that only emerge at higher throughput. In practice, this translates to designing fully automated QC testing workcells where sample processing, analytical execution, and data capture operate as a unified system. These workcells integrate liquid handling, analytical instruments, environmental controls, and robotic sample transport within a controlled footprint, dynamically orchestrated through software that manages scheduling, resource allocation, and workflow prioritization in real time. The shift from discrete manual steps to continuous automated flow fundamentally changes how capacity is utilized. Instruments run with higher duty cycles, samples move through testing with minimal idle time, and operator intervention shifts from execution to exception handling and oversight.

Equally important is the optimization of the surrounding infrastructure that enables automated execution. This includes physical lab layout, instrument adjacency, material flow paths, environmental controls, and digital infrastructure, such as scheduling engines, data pipelines, and integration with LIMS, MES, and QMS systems. A purpose-built automated workcell minimizes these friction points through intentional physical and digital architecture. Sample handlers position material precisely where instruments expect it. Barcode readers verify identity at every transfer point. Environmental sensors continuously monitor conditions that could affect assay performance. Automated liquid handlers prepare and dispense reagents with precision and traceability that manual pipetting cannot match at scale. The workcell becomes a closed-loop system in which the physical execution environment and digital tracking infrastructure are fully integrated. Small design decisions at this layer, such as how samples are staged, how reagents are kitted, how instruments are triggered, and how data are handed off, can have an outsized impact on throughput, reliability, and operator workload when multiplied across hundreds or thousands of runs.

End-to-end optimization also introduces a shift in how success is measured. Traditional metrics focused on individual assay performance are supplemented with system-level indicators, such as throughput per shift, turnaround time variability, first-pass success rates, and recovery time from disruptions. For automated workcells, additional performance indicators become critical: equipment uptime and mean time between failures, sample throughput per instrument per shift, utilization rates across parallel processing stations, and the frequency of manual interventions required to resolve exceptions. These metrics expose whether the workcell design truly enables autonomous operation or merely automates individual tasks while leaving coordination gaps that still require human intervention. Closed feedback loops built around these indicators allow workflows to be continuously refined as volumes grow, assays change, or new sites come online.

By combining structured experimentation, system-level metrics, and intentional infrastructure design, QC organizations can move beyond static automation toward adaptive, high-throughput operations. The result is an end-to-end workflow that is not only automated but resilient and capable of scaling with demand while maintaining data integrity, regulatory compliance, and operational control.

Overcoming mindset challenges

Changes to end-to-end workflow infrastructure, the introduction of fully automated QC methods, and the shift to a fully digitized operational ecosystem represent a fundamental departure from traditional QC testing. For many organizations, this transition is not an incremental improvement but a complete rethinking of how work is performed, monitored, and controlled. The impact extends beyond new instruments or software; it requires teams to learn unfamiliar technologies, adopt new technical paradigms, and trust systems that operate with less direct human intervention than they are accustomed to.

These changes often surface challenges in adoption and alignment. Automated workflows can feel opaque compared to manual processes that rely on hands-on execution and experiential knowledge. The introduction of orchestration layers, data pipelines, and algorithm-driven scheduling can create a perceived loss of control, even when these systems are designed to increase consistency and reliability. Without a clear understanding of how individual steps connect to the broader system, and how decisions are made within it, teams may default to familiar manual workarounds, limiting the effectiveness of automation investments.

The required mindset shift is significant. Traditional QC environments are built around localized ownership, static procedures, and reactive problem-solving. High-throughput automated QC demands a move toward system-level thinking, proactive design, and trust in standardized, repeatable workflows. This transition can be difficult, particularly in regulated environments where caution is ingrained and deviations from established practices are understandably scrutinized. The challenge is amplified in organizations where automation is layered onto legacy processes rather than designed as a cohesive end-to-end system from the start.

To alleviate these challenges, a methodical and transparent approach is essential. Teams must be brought along in understanding how automated systems and assay workflows are designed, validated, and operated, not just trained on how to use them. This includes clearly articulating system behavior, failure modes, and recovery strategies; demonstrating how data flows from execution to review; and showing how automation enhances, rather than replaces, scientific and quality judgment. By grounding the transition in shared understanding, incremental trust-building, and measurable performance improvements, organizations can shift mindsets from skepticism to ownership and unlock the full value of automated, scalable QC operations.

About the author

John Cesarek is the senior director of automation engineering at Cellares, where he leads the design and development of the integrated digital, scientific, and operational workflows for automated quality control in cell therapy manufacturing.